ME02622B - Pripremanje nalmefen hidrohlorida od naltreksona - Google Patents

Pripremanje nalmefen hidrohlorida od naltreksona

Info

Publication number
ME02622B
ME02622B MEP-2016-40A MEP4016A ME02622B ME 02622 B ME02622 B ME 02622B ME P4016 A MEP4016 A ME P4016A ME 02622 B ME02622 B ME 02622B
Authority
ME
Montenegro
Prior art keywords
mthf
phase
naltrexone
methyltriphenylphosphonium
nalmefene
Prior art date
Application number
MEP-2016-40A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Faveri Carla De
Mauro Casarin
Michele Brusegan
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43222172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02622(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of ME02622B publication Critical patent/ME02622B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08Oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
MEP-2016-40A 2009-05-25 2010-05-21 Pripremanje nalmefen hidrohlorida od naltreksona ME02622B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200900650 2009-05-25
US18102209P 2009-05-26 2009-05-26
EP10720257.4A EP2435439B8 (en) 2009-05-25 2010-05-21 Preparation of nalmefene hydrochloride from naltrexone
PCT/DK2010/050110 WO2010136039A1 (en) 2009-05-25 2010-05-21 Preparation of nalmefene hydrochloride from naltrexone

Publications (1)

Publication Number Publication Date
ME02622B true ME02622B (me) 2017-06-20

Family

ID=43222172

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-40A ME02622B (me) 2009-05-25 2010-05-21 Pripremanje nalmefen hidrohlorida od naltreksona

Country Status (35)

Country Link
US (1) US8598352B2 (enExample)
EP (1) EP2435439B8 (enExample)
JP (1) JP5794980B2 (enExample)
KR (1) KR101716522B1 (enExample)
CN (1) CN102459276B (enExample)
AR (1) AR076891A1 (enExample)
AU (1) AU2010252392B2 (enExample)
BR (1) BRPI1010975B1 (enExample)
CA (1) CA2763093C (enExample)
CL (1) CL2011002974A1 (enExample)
CO (1) CO6470832A2 (enExample)
CR (1) CR20110612A (enExample)
DK (1) DK2435439T3 (enExample)
DO (1) DOP2011000362A (enExample)
EA (1) EA019331B1 (enExample)
ES (1) ES2564006T3 (enExample)
GE (1) GEP20146190B (enExample)
HR (1) HRP20160110T1 (enExample)
HU (1) HUE026892T2 (enExample)
IL (1) IL216422A (enExample)
MA (1) MA33368B1 (enExample)
ME (1) ME02622B (enExample)
MX (1) MX2011012502A (enExample)
MY (1) MY158251A (enExample)
NZ (1) NZ596988A (enExample)
PL (1) PL2435439T3 (enExample)
RS (1) RS54599B1 (enExample)
SG (1) SG176205A1 (enExample)
SI (1) SI2435439T1 (enExample)
SM (1) SMT201600061B (enExample)
TN (1) TN2011000590A1 (enExample)
TW (1) TWI469985B (enExample)
UA (1) UA106752C2 (enExample)
WO (1) WO2010136039A1 (enExample)
ZA (1) ZA201108659B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2802295C (en) 2010-06-11 2016-09-20 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
HRP20170379T1 (hr) 2010-11-05 2017-05-05 H. Lundbeck A/S Postupak proizvodnje naltreksona
CN103012416B (zh) * 2011-09-28 2015-07-01 辽宁海思科制药有限公司 一种盐酸纳美芬的制备方法
TWI560170B (en) * 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
CN102584840A (zh) * 2011-12-28 2012-07-18 南京优科生物医药有限公司 一种制备纳美芬化合物的方法
WO2013164383A1 (en) 2012-05-03 2013-11-07 H. Lundbeck A/S Method for the manufacturing of naltrexone
US20140005216A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
CN103204859B (zh) * 2013-04-25 2015-12-02 四川海思科制药有限公司 一种盐酸纳美芬化合物及其制备方法
AR096851A1 (es) 2013-07-11 2016-02-03 H Lundbeck As Sales que no forman hidratos ni solvatos de nalmefeno
JP6448645B2 (ja) 2013-12-20 2019-01-09 ハー・ルンドベック・アクチエゼルスカベット メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用
SG10201809280PA (en) 2014-04-22 2018-11-29 Otsuka Pharma Co Ltd Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
CN104513251A (zh) * 2014-11-28 2015-04-15 安徽悦康凯悦制药有限公司 一种盐酸纳美芬的制备方法
US9757372B2 (en) * 2015-03-25 2017-09-12 Taiwanj Pharmaceuticals Co., Ltd. Toll-like receptor 4 antagonists and use in autoimmune liver diseases
RU2712232C1 (ru) * 2018-10-05 2020-01-27 Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства Улучшенный способ получения налмефена из налтрексона
US10927121B1 (en) 2019-12-20 2021-02-23 Southwest Research Institute Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
CA3196369A1 (en) 2020-11-02 2022-05-05 C. Frederick M. Huntley Process for purifying noroxymorphone
US20240109907A1 (en) 2021-01-28 2024-04-04 Rhodes Technologies Process for crystallizing nalmefene hydrochloride
CN117843650A (zh) * 2023-12-27 2024-04-09 南京海纳医药科技股份有限公司 一种盐酸纳美芬的精制方法
CN117986261B (zh) * 2024-04-02 2024-06-18 成都瑞尔医药科技有限公司 一种盐酸纳美芬母液的回收套用方法
CN119080788A (zh) * 2024-08-19 2024-12-06 南京海鲸药业股份有限公司 一种盐酸纳美芬杂质的去除监控系统及去除方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341764A (en) 1980-03-05 1982-07-27 Cutter Laboratories, Inc. Method of preparing fibronectin and antihemophilic factor
US4322426A (en) 1980-04-28 1982-03-30 E. I. Du Pont De Nemours And Company 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
US4535157A (en) * 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) * 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
US4880813A (en) * 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
US7687646B2 (en) 2006-03-28 2010-03-30 Azad Pharmaceutical Ingredients, Ag Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene

Also Published As

Publication number Publication date
SMT201600061B (it) 2016-07-01
CA2763093C (en) 2017-03-07
BRPI1010975B1 (pt) 2021-08-24
KR101716522B1 (ko) 2017-03-14
TWI469985B (zh) 2015-01-21
MA33368B1 (fr) 2012-06-01
MX2011012502A (es) 2011-12-12
UA106752C2 (uk) 2014-10-10
GEP20146190B (en) 2014-11-10
AR076891A1 (es) 2011-07-13
DOP2011000362A (es) 2012-07-15
HUE026892T2 (en) 2016-07-28
JP2012527489A (ja) 2012-11-08
PL2435439T3 (pl) 2016-05-31
TW201043634A (en) 2010-12-16
CO6470832A2 (es) 2012-06-29
IL216422A (en) 2015-06-30
IL216422A0 (en) 2012-02-29
HRP20160110T1 (hr) 2016-03-11
BRPI1010975A2 (pt) 2015-10-20
EP2435439B8 (en) 2016-05-18
EP2435439A1 (en) 2012-04-04
EA201171461A1 (ru) 2012-05-30
MY158251A (en) 2016-09-30
SG176205A1 (en) 2011-12-29
US8598352B2 (en) 2013-12-03
AU2010252392B2 (en) 2014-10-23
CA2763093A1 (en) 2010-12-02
CN102459276A (zh) 2012-05-16
AU2010252392A1 (en) 2012-01-12
ES2564006T3 (es) 2016-03-17
JP5794980B2 (ja) 2015-10-14
NZ596988A (en) 2013-03-28
KR20120023704A (ko) 2012-03-13
EA019331B1 (ru) 2014-02-28
RS54599B1 (sr) 2016-08-31
CR20110612A (es) 2012-02-22
CL2011002974A1 (es) 2012-04-13
DK2435439T3 (en) 2016-02-29
ZA201108659B (en) 2013-02-27
WO2010136039A1 (en) 2010-12-02
EP2435439B1 (en) 2016-01-06
TN2011000590A1 (en) 2013-05-24
US20120123123A1 (en) 2012-05-17
CN102459276B (zh) 2016-09-21
SI2435439T1 (sl) 2016-06-30

Similar Documents

Publication Publication Date Title
ME02622B (me) Pripremanje nalmefen hidrohlorida od naltreksona
ME02316B (me) Imidazopiridazini kao inhibitori akt kinaze
JP2012527489A5 (enExample)
Ersoy et al. Mantle source characteristics and melting models for the early-middle Miocene mafic volcanism in Western Anatolia: Implications for enrichment processes of mantle lithosphere and origin of K-rich volcanism in post-collisional settings
PT2118090E (pt) Processo para a preparação de um derivado de benzimidazole
CN102127110B (zh) 一种草铵膦溶液的分离提纯方法
AU2012356770A8 (en) Polycarboxylic acid extraction
MY161613A (en) Method for synthesizing rare earth metal extractant
CN107382803B (zh) 一种β-羟基苯基硒醚化合物的制备方法
PH12013500029A1 (en) Method for synthesizing rare earth metal extractant
RU2020114951A (ru) Термопластичныe полиоксазолидоны из диизоцианатов и производных диглицидилового эфира 2-фенил-1,3-пропандиола
CN105153258B (zh) 3-β-羟基-雄甾-17-酮的制备方法
CN104693195A (zh) 一种苯吡唑草酮的制备方法
SI2763948T1 (en) Procedure for the isolation of an ingenol
JP2013534911A5 (enExample)
SI2635592T1 (en) Method for obtaining phytosterols and/or tocopherols from residue of a distillation of the esters of vegetable oils, preferably from distillation residue from a transesterification of vegetable oils
EP3118194B1 (en) Method for producing 2-acyliminopyridine derivative
HRP20170497T1 (hr) Postupak dobivanja nalmefen hidroklorida
CN102850379B (zh) 甲氧头孢中间体7-mac的合成方法
CN101698669B (zh) 一种7-苯乙酰氨基-3-乙烯基-4-对甲氧基苄基头孢菌素的合成方法
CN106380398A (zh) 一种溴乙酸叔丁酯的绿色合成方法
CN103555969B (zh) 一种钾钠分离新方法
CN104031003B (zh) Mbt的复合溶剂精制法
CN103665078A (zh) 一种17α-羟基甾体酯的制备方法
WO2008026219A3 (en) Novel polymorphs of rimonabant